

## NIH AIDS Reagent Program

20301 Century Boulevard Building 6, Suite 200 Germantown, MD 20874 USA

Phone: 240 686 4740 Fax: 301 515 4015 aidsreagent.org

## **DATA SHEET**

Reagent: Human NF-κB p65 Expression Vector (pRSV-RelA p65)

Catalog Number: 2626

94094 Lot Number:

**Release Category:** C

Provided: 1 vial ampicillin-resistant transformed XL-1 Blue bacteria.

GenBank: M62399

**Description:** Contains a 1680 bp HindIII-BamHI insert encoding the NF-кВ RelA region. The BamHI

site was destroyed during cloning.

Directs the expression of RelA in eukaryotic cells. The 5' sequence is AAGCTT CACC Special Characteristics:

ATG G, which contains a HindIII site, Kozak sequence (underlined) and methionine

initiation site (bold).

Plasmid Map

Recommended

Storage:

-70°C.

**Contributor:** Dr. Gary Nabel and Dr. Neil Perkins.

References: Duckett CS, Perkins ND, Kowalik TF, Schmid RM, Huang ES, Baldwin AS Jr, Nabel GJ.

Dimerization of NF-κB2 with RelA (p65) regulates DNA binding, transcriptional activation, and inhibition by an I κBa (MAD-3). Mol Cell Biol 13:1315, 1993.

Gorman C, Padmanabhan Ŕ, Howard BH. High efficiency DNA-mediated transformation

of primate cells. Science 221:551-553, 1983.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 03/25/2019 Page 1 of 2

NOTE: Acknowledgment for publications should read "The following reagent was obtained
---

through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Human NF-κΒ p65 Expression Vector (pRSV-RelA p65) from Dr. Gary Nabel and Dr. Neil Perkins (cat# 2626)." Also include the references cited above in any publications.

Last Updated: March 25, 2019

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 03/25/2019 Page 2 of 2